About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...

The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted the vital role of advanced therapies in supporting the UK Government’s goal of becoming a top three global life sciences economy by ...

"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...

The cell and gene therapy field has been moving at breakneck speed over the past year. The ASGCT (American Society of Gene and Cell Therapy) meeting is an incredibly important annual event for the ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

Over the last 15 years, I have witnessed how cell and gene therapy (CGT) has evolved in many ways, spanning from research and development to manufacturing. Breakthroughs such as CAR-T and gene therapy ...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy ...

Klotho Neurosciences, Inc. (NASDAQ: KLTO ) (the "Company" or "Klotho"), a U.S.-based biogenetics company, announces it has ...

Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from ...

In June, the Centers for Medicare & Medicaid Services (CMS) will name the participating states for the agency’s new Cell and Gene Therapy (CGT) Access Model. One state has already started ...

(L-R) Berlin Mayor Kai Wegner, pharmacologist Heyo K. Kroemer, Germany's Finance Minister Lars Klingbeil, Bayer board member Stefan Oelrich, and Research Minister Dorothee Baer attend the ...

Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy ...